IsoRay, Inc. (ISR)
Stock Price:
$0.400 USD
0.000 (0.00%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $0.401 +0.001 (0.25%) Oct 21, 4:50 PM
Key Info
| Market Cap |
27.56M |
| Revenue (ttm) |
9.68M |
| Net Income (ttm) |
-3.45M |
| Shares Out |
68.90M |
| EPS (ttm) |
-0.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$0.400 |
| Previous Close |
$0.400 |
| Change ($) |
0.000 |
| Change (%) |
0.00% |
| Day's Open |
0.412 |
| Day's Range |
0.390 - 0.430 |
| Day's Volume |
1,803,253 |
| 52-Week Range |
0.288 - 1.060 |
More Stats
| Market Cap |
27.56M |
| Enterprise Value |
25.99M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
68.90M |
| Float |
68.01M |
| EPS (basic) |
-0.05 |
| EPS (diluted) |
-0.05 |
| FCF / Share |
-0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.31M |
| Short Ratio |
3.22 |
| Short % of Float |
1.93% |
| Beta |
1.93 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.85 |
| PB Ratio |
6.92 |
| Revenue |
9.68M |
| Operating Income |
-3.48M |
| Net Income |
-3.45M |
| Free Cash Flow |
-3.91M |
| Net Cash |
1.57M |
| Net Cash / Share |
0.02 |
| Gross Margin |
52.93% |
| Operating Margin |
-35.91% |
| Profit Margin |
-35.70% |
| FCF Margin |
-40.43% |
| ROA |
-23.98% |
| ROE |
-51.42% |
| ROIC |
-64.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$1.28*
(220.00% upside)
Low
1.00
Current: $0.400
High
1.60
Target: 1.28
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 9.68 | 7.31 | 5.92 | 4.76 | 4.77 | 4.61 | 4.22 | 4.53 | 5.07 | 5.24 |
| Revenue Growth | 32.35% | 23.48% | 24.41% | -0.17% | 3.54% | 9.17% | -6.76% | -10.76% | -3.2% | - |
| Gross Profit | 5.12 | 3.05 | 1.84 | 0.84 | 0.13 | 0.17 | -0.20 | 0.15 | 0.70 | 1.16 |
| Operating Income | -3.48 | -5.25 | -6.73 | -6.31 | -5.08 | -4.34 | -4.59 | -4.07 | -3.60 | -2.96 |
| Net Income | -3.45 | -5.14 | -6.70 | -6.16 | -4.71 | -3.68 | -5.96 | -3.86 | -3.49 | -2.84 |
| Shares Outstanding | 67.60 | 67.04 | 55.16 | 55.02 | 55.02 | 54.88 | 42.68 | 34.42 | 28.62 | 25.13 |
| Earnings Per Share | -0.05 | -0.08 | -0.12 | -0.11 | -0.09 | -0.07 | -0.16 | -0.11 | -0.12 | -0.11 |
| Operating Cash Flow | -3.64 | -5.05 | -5.71 | -5.71 | -3.88 | -3.52 | -3.23 | -3.06 | -2.45 | -2.42 |
| Capital Expenditures | -0.27 | -0.41 | -0.34 | -0.54 | -0.48 | -0.13 | -0.02 | -0.01 | -0.06 | -0.14 |
| Free Cash Flow | -3.91 | -5.46 | -6.05 | -6.26 | -4.36 | -3.66 | -3.25 | -3.06 | -2.50 | -2.56 |
| Cash & Equivalents | 2.57 | 5.51 | 3.61 | 9.15 | 15.54 | 19.88 | 23.27 | 3.08 | 2.85 | 2.29 |
| Total Debt | 1.01 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 1.57 | 5.51 | 3.61 | 9.15 | 15.54 | 19.88 | 23.27 | 3.08 | 2.85 | 2.29 |
| Assets | 8.70 | 9.42 | 7.46 | 12.27 | 18.10 | 23.00 | 26.55 | 7.06 | 7.51 | 7.89 |
| Liabilities | 2.98 | 1.74 | 2.43 | 1.67 | 1.70 | 2.22 | 2.59 | 1.69 | 1.69 | 1.44 |
| Book Value | 5.72 | 7.68 | 5.03 | 10.60 | 16.40 | 20.78 | 23.96 | 5.37 | 5.82 | 6.45 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IsoRay, Inc. |
| Country |
United States |
| Employees |
53 |
| CEO |
Lori A. Woods |
Stock Information
| Ticker Symbol |
ISR |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NYSEAMERICAN: ISR |
Description
Isoray, through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.